Precision Optics (NASDAQ:POCI – Get Free Report) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.
Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Precision Optics in a report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Precision Optics currently has a consensus rating of “Sell”.
Get Our Latest Analysis on POCI
Precision Optics Stock Performance
Precision Optics (NASDAQ:POCI – Get Free Report) last posted its quarterly earnings data on Monday, September 28th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.05. Precision Optics had a negative net margin of 11.51% and a negative return on equity of 23.92%. The company had revenue of $8.77 million during the quarter, compared to analysts’ expectations of $7.10 million.
Institutional Investors Weigh In On Precision Optics
An institutional investor recently raised its position in Precision Optics stock. Needham Investment Management LLC increased its holdings in Precision Optics Corp. (NASDAQ:POCI – Free Report) by 2.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 720,000 shares of the company’s stock after acquiring an additional 20,000 shares during the period. Needham Investment Management LLC owned about 9.33% of Precision Optics worth $3,013,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 13.71% of the company’s stock.
About Precision Optics
Precision Optics Corporation, Inc (NASDAQ: POCI) designs and manufactures advanced optical and imaging systems, primarily for the medical device market. The company develops products used in minimally invasive surgery, including endoscopes, surgical cameras, and specialized visualization systems that help physicians view internal anatomy during diagnostic and therapeutic procedures.
Its product portfolio includes reusable and single-use endoscopes, three-dimensional imaging systems, fluorescence imaging technologies, and custom optical components and assemblies.
Recommended Stories
- Five stocks we like better than Precision Optics
- Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?
- The AI Buildout Needs Power It Cannot Get: 4 Energy Stocks Already Have It
- McDonald’s Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers?
- MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning?
Receive News & Ratings for Precision Optics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Optics and related companies with MarketBeat.com's FREE daily email newsletter.
